Claims
- 1. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence of SEQ ID NO:3; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising at least 200 contiguous amino acids of SEQ ID NO:3.
- 2. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:2; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:2 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 500 contiguous nucleotides of SEQ ID NO:2.
- 3. A vector or host cell comprising the isolated nucleic acid molecule of claim 2.
- 4. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 1 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 1.
- 5. A composition comprising an antagonist compound identified by a method of claim 4.
- 6. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 2, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 2 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 2.
- 7. A composition comprising an antagonist compound identified according to the method of claim 6.
- 8. A method for the treatment of an individual having need to inhibit a polypeptide of claim 1, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 5 or claim 7.
- 9. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 1.
- 10. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 9.
- 11. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 50% identity to the amino acid sequence SEQ ID NO:15; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:15; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:15; and (d) a polypeptide comprising at least 250 contiguous amino acids of SEQ ID NO:15.
- 12. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 50% identity to the nucleotide sequence of SEQ ID NO:14; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:14 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:14 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 750 contiguous nucleotides of SEQ ID NO:14.
- 13. A vector or host cell comprising the isolated nucleic acid molecule of claim 12.
- 14. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 11, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 11 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 11.
- 15. A composition comprising an antagonist compound identified by a method of claim 14.
- 16. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 12, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 12 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 12.
- 17. A composition comprising an antagonist compound identified according to the method of claim 16.
- 18. A method for the treatment of an individual having need to inhibit a polypeptide of claim 11, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 15 or claim 17.
- 19. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 11.
- 20. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 19.
- 21. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:18; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:18; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:18; and (d) a polypeptide comprising at least 200 contiguous amino acids of SEQ ID NO:18.
- 22. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:17; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:17 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:17 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 600 contiguous nucleotides of SEQ ID NO:17.
- 23. A vector or host cell comprising the isolated nucleic acid molecule of claim 22.
- 24. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 21, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 21 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 21.
- 25. A composition comprising an antagonist compound identified by a method of claim 24.
- 26. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 22, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 22 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 22.
- 27. A composition comprising an antagonist compound identified according to the method of claim 26.
- 28. A method for the treatment of an individual having need to inhibit a polypeptide of claim 21, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 25 or claim 27.
- 29. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 21.
- 30. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 29.
- 31. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:30; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:30; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:30; and (d) a polypeptide comprising at least 90 contiguous amino acids of SEQ ID NO:30.
- 32. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:29; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:29 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:29 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 300 contiguous nucleotides of SEQ ID NO:29.
- 33. A vector or host cell comprising the isolated nucleic acid molecule of claim 32.
- 34. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 31, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 31 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 31.
- 35. A composition comprising an antagonist compound identified by a method of claim 34.
- 36. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 32, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 32 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 32.
- 37. A composition comprising an antagonist compound identified according to the method of claim 36.
- 38. A method for the treatment of an individual having need to inhibit a polypeptide of claim 31, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 35 or claim 37.
- 39. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 31.
- 40. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 39.
- 41. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 55% identity to the amino acid sequence SEQ ID NO:6; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:6; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:6; and (d) a polypeptide comprising at least 160 contiguous amino acids of SEQ ID NO:6.
- 42. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 55% identity to the nucleotide sequence of SEQ ID NO:5; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:5 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:5 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 500 contiguous nucleotides of SEQ ID NO:5.
- 43. A vector or host cell comprising the isolated nucleic acid molecule of claim 42.
- 44. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 41, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 41 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 41.
- 45. A composition comprising an antagonist compound identified by a method of claim 44.
- 46. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 42, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 42 to a compound under conditions suitable for the expression of the target nucleic acid molecule; . b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 42.
- 47. A composition comprising an antagonist compound identified according to the method of claim 46.
- 48. A method for the treatment of an individual having need to inhibit a polypeptide of claim 41, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 45 or claim 47.
- 49. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 41.
- 50. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 49.
- 51. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:9; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:9; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:9; and (d) a polypeptide comprising at least 250 contiguous amino acids of SEQ ID NO:9.
- 52. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:8; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:8 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 800 contiguous nucleotides of SEQ ID NO:8.
- 53. A vector or host cell comprising the isolated nucleic acid molecule of claim 52.
- 54. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 51, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 51 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 51.
- 55. A composition comprising an antagonist compound identified by a method of claim 54.
- 56. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 52, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 52 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 52.
- 57. A composition comprising an antagonist compound identified according to the method of claim 56.
- 58. A method for the treatment of an individual having need to inhibit a polypeptide of claim 51, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 55 or claim 57.
- 59. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 51.
- 60. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 59.
- 61. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:12; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:12; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:12; and (d) a polypeptide comprising at least 200 contiguous amino acids of SEQ ID NO:12.
- 62. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:11; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO :11 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:11 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 800 contiguous nucleotides of SEQ ID NO:11.
- 63. A vector or host cell comprising the isolated nucleic acid molecule of claim 62.
- 64. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 61, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 61 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 61.
- 65. A composition comprising an antagonist compound identified by a method of claim 64.
- 66. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 62, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 62 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 62.
- 67. A composition comprising an antagonist compound identified according to the method of claim 66.
- 68. A method for the treatment of an individual having need to inhibit a polypeptide of claim 61, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 65 or claim 67.
- 69. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 61.
- 70. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 69.
- 71. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:21; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:21; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:21; and (d) a polypeptide comprising at least 150 contiguous amino acids of SEQ ID NO:21.
- 72. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:20; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:20 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:20 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 400 contiguous nucleotides of SEQ ID NO:20.
- 73. A vector or host cell comprising the isolated nucleic acid molecule of claim 72.
- 74. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 71, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 71 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 71.
- 75. A composition comprising an antagonist compound identified by a method of claim 74.
- 76. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 72, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 72 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 72.
- 77. A composition comprising an antagonist compound identified according to the method of claim 76.
- 78. A method for the treatment of an individual having need to inhibit a polypeptide of claim 71, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 75 or claim 77.
- 79. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 71.
- 80. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 79.
- 81. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:24; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:24; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:24; and (d) a polypeptide comprising at least 200 contiguous amino acids of SEQ ID NO:24.
- 82. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:23; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:23 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:23 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 600 contiguous nucleotides of SEQ ID NO:23.
- 83. A vector or host cell comprising the isolated nucleic acid molecule of claim 82.
- 84. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 81, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 81 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 81.
- 85. A composition comprising an antagonist compound identified by a method of claim 84.
- 86. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 82, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 82 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 82.
- 87. A composition comprising an antagonist compound identified according to the method of claim 86.
- 88. A method for the treatment of an individual having need to inhibit a polypeptide of claim 81, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 85 or claim 87.
- 89. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 81.
- 90. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 89.
- 91. An isolated polypeptide selected from the group consisting of: (a) a polypeptide comprising an amino acid sequence having at least 45% identity to the amino acid sequence SEQ ID NO:27; (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:27; (c) a polypeptide that consists essentially of the amino acid sequence of SEQ ID NO:27; and (d) a polypeptide comprising at least 400 contiguous amino acids of SEQ ID NO:27.
- 92. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having at least 45% identity to the nucleotide sequence of SEQ ID NO:26; (b) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:26 or a complement thereof; (c) a nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:26 or a fragment thereof; and (d) a nucleic acid molecule comprising at least 140 contiguous nucleotides of SEQ ID NO:26.
- 93. A vector or host cell comprising the isolated nucleic acid molecule of claim 92.
- 94. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 91, the method comprising the steps of:
a) exposing a sample comprising a polypeptide of claim 91 to a compound; and b) detecting antagonist activity in the sample, wherein said antagonist activity identifies said compound as an effective antagonist of a polypeptide of claim 91.
- 95. A composition comprising an antagonist compound identified by a method of claim 94.
- 96. A method for screening an antagonist compound for effectiveness in altering expression of a target nucleic acid molecule of claim 92, said method comprising the steps of:
a) exposing a sample comprising a target nucleic acid molecule of claim 92 to a compound under conditions suitable for the expression of the target nucleic acid molecule; b) detecting altered expression of the target nucleic acid molecule; and c) comparing the expression of the target nucleic acid molecule in the presence of the compound and in the absence of the compound, wherein a decrease in expression identifies an antagonist compound effective in altering the expression of the target nucleic acid molecule of claim 92.
- 97. A composition comprising an antagonist compound identified according to the method of claim 96.
- 98. A method for the treatment of an individual having need to inhibit a polypeptide of claim 91, said method comprising administering to the individual a therapeutically effective amount of the antagonist of claim 95 or claim 97.
- 99. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic polypeptide of claim 91.
- 100. A method of preventing or treating a microbial infection in a mammal by administering to said mammal a vaccine composition of claim 99.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of International Application No. PCT/US02/22979, filed Jul. 18, 2002, which was published in English under PCT Article 21(2), which claims the benefit of U.S. Provisional Application 60/306,212, filed Jul. 18, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60306212 |
Jul 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US02/22979 |
Jul 2002 |
US |
Child |
10758979 |
Jan 2004 |
US |